{
  "abstract": "Background and Importance Ofatumumab, an anti-CD20 monoclonal antibody, has shown high efficacy and a favourable safety profile in patients with Multiple Sclerosis (MS) in clinical trials. Real-world data are essential to assess its effectiveness, tolerability and persistence under routine clinical conditions.Aim and Objectives To evaluate the effectiveness, safety and persistence of ofatumumab in patients with MS treated in a tertiary hospital.Material and Methods A retrospective observational study was conducted including all patients with relapsing-remitting or secondary progressive multiple sclerosis (RRMS; SPMS), who initiated Ofatumumab between January 2023 and August 2025 in a tertiary hospital. Demographic, clinical, and treatment-related data were obtained from electronic medical records. Variables included: age, sex, previous disease-modifying therapies (DMTs), treatment persistence, adverse events, reasons for discontinuation, Expanded Disability Status Scale (EDSS). Descriptive statistics were used to analyse the data.Results 54 patients were included (57% female; mean age 41.6± 12.5 years), of whom two with SPMS. 48% patients were naïve, but the majority had received ≥2 prior DMTs , mainly interferons (41,3%), , dimethyl fumarate (34,5%), glatiramer acetate (31%), cladribine (20,7%), teriflunomide (17,2%) and natalizumab (6,9%). The main reasons for discontinuation were adverse events (40%), disease progression (13%), and JC virus positivity (3.7%), among other reasons. The criterion for starting or switching to ofatumumab was to have high disease activity or progression. It is noticed that two patients switched from ocrelizumab to ofatumumab: one due to infusion-related adverse effects and another for logistical difficulties attending the hospital. At data cut-off, 100% of patients remained on treatment, with an average persistence of 13.8 months and maintaining the stability of the EDSS with an average of 2. Ofatumumab was well tolerated in most cases: the most frequent adverse event was a flu-like syndrome (5.6%) and isolated local reactions (≤2%).Conclusion and Relevance In this real-world cohort, ofatumumab showed good tolerability and sustained clinical stability. These findings reinforce ofatumumab as an effective and convenient treatment option, particularly for patients requiring self-administered anti-CD20 therapy.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Pharmacy, Santa Cruz De Tenerife, Spain"
      ],
      "name": "J Gonzalez Chavez"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Pharmacy, Santa Cruz De Tenerife, Spain"
      ],
      "name": "A Dominguez Hernandez"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Neurology, Santa Cruz De Tenerife, Spain"
      ],
      "name": "MA Hernandez Perez"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Neurology, Santa Cruz De Tenerife, Spain"
      ],
      "name": "C Villar Van Den Weygert"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Neurology, Santa Cruz De Tenerife, Spain"
      ],
      "name": "Y Contreras Martin"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Neurology, Santa Cruz De Tenerife, Spain"
      ],
      "name": "C Sole Violan"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Pharmacy, Santa Cruz De Tenerife, Spain"
      ],
      "name": "E Ramos Santana"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Pharmacy, Santa Cruz De Tenerife, Spain"
      ],
      "name": "M Suarez Gonzalez"
    },
    {
      "affiliations": [
        "Hospital Universitario Nuestra Señora De Candelaria, Pharmacy, Santa Cruz De Tenerife, Spain"
      ],
      "name": "P Diaz Ruiz"
    }
  ],
  "title": "4CPS-162 Real-world evidence with ofatumumab in multiple sclerosis",
  "uid": "d083f1ad-596f-5f6d-901d-38a3d29987e5"
}